weight loss drug news today glp-1 medications could cut US mortality by 6.4%, new study finds Are you eligible? Medicare's new

The trial demonstrated a significant reduction of 25% in the primary composite outcome of cardiovascular death and first HFH (19.4% versus 24.7% [HR 0.75

Semaglutide is associated with a four times higher risk of NAION when used for treating Type 2 diabetes and a seven times higher risk when used for obesity, according to the study

Ancillary analysis We used metformin as a control in the secondary analysis

Check storage integrity

A separate 12-week trial at 30mg showed an average loss of 8.1 kilograms, with 95.8 percent of participants achieving at least 5 percent body weight loss

Taking Contrave with a monoamine oxidase inhibitor (MAOI) or within 14 days of stopping one may increase the risk of a severe increase in blood pressure (hypertensive crisis)